ERLOTINIB Side Effects

6869182-6 | Chronic Obstructive Pulmonary Disease, Fatigue, Nausea
on Jul 22, 2010 Male patient from UNITED STATES , weighting 127.2 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: chronic obstructive pulmonary disease, fatigue, nausea (What is nausea?). Erlotinib dosage: Erlotinib 150mg Daily Oral. During the same period patient was treated with BEVACIZUMAB (Bevacizumab 15mg/kg Every 21 Days Intravenous) (View Bevacizumab Review and Bevacizumab Label ). Patient was hospitalized.

6687625-8 | Cholangitis Acute
Patient was taking Erlotinib (View Usage). Patient had the following side effects: cholangitis acute on Mar 30, 2010 from BULGARIA Additional patient health information: Male patient , 57 years of age, was diagnosed with pancreatic carcinoma and. Erlotinib dosage: (qd), Oral. During the same period patient was treated with TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ), KREON (PANCREATIN) (View Kreon (pancreatin) Review and Kreon (pancreatin) Label ), INSULATARD NPH HUMAN (View Insulatard Nph Human Review and Insulatard Nph Human Label ). Patient was hospitalized.

6687474-0 | Gastric Haemorrhage, Myocardial Infarction
Adverse event was reported on Apr 16, 2010 by a Male patient taking Erlotinib (View Usage) (Dosage: 150 Mg Every Day Po) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , 64 years of age, weighting 133.4 lb, After Erlotinib was administered, patient had the following side effects: gastric haemorrhage, myocardial infarction. Patient was hospitalized.

6678845-7 | Cellulitis, Head And Neck Cancer, Infection, Malignant Neoplasm Progression
on Apr 12, 2010 Female patient from UNITED STATES , 51 years of age, weighting 143.3 lb, was diagnosed with paranasal sinus and nasal cavity malignant neoplasm and was treated with Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: cellulitis (What is cellulitis?), head and neck cancer (What is head and neck cancer?), infection (What is infection?), malignant neoplasm progression. Erlotinib dosage: 300 Mg Day 2 Po ; 150 Mg Day 3-17 Po. During the same period patient was treated with CISPLATIN (75 Mg/m2 Day 1 Iv) (View Cisplatin Review and Cisplatin Label ), PACLITAXEL (175 Mg/m2 Day 1 Iv) (View Paclitaxel Review and Paclitaxel Label ). Patient was hospitalized.


6619490-9 |
on Feb 17, 2010 Female patient from UNITED STATES , 76 years of age, weighting 138.0 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). . Erlotinib dosage: Oral. During the same period patient was treated with BEVACIZUMAB ((992 Mg,q3w), Intravenous) (View Bevacizumab Review and Bevacizumab Label ).

6582867-4 | Chills, Cough, Decreased Appetite, Diarrhoea, Faecal Incontinence, Hepatic Enzyme Increased, Nausea, Pyrexia
Patient was taking Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: chills, cough, decreased appetite, diarrhoea, faecal incontinence, hepatic enzyme increased, nausea (What is nausea?), pyrexia on Feb 12, 2010 from UNITED STATES Additional patient health information: Male patient , 74 years of age, weighting 233.1 lb, was diagnosed with head and neck cancer (What is head and neck cancer?) and. Erlotinib dosage: 150 Mg Every Day Po. Patient was hospitalized.

6538314-1 | Intestinal Obstruction
Adverse event was reported on Jan 12, 2010 by a Male patient taking Erlotinib (View Usage) (Dosage: 100mg Qd Po) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , weighting 186.0 lb, Patient experienced the following unwanted or unexpected effects: intestinal obstruction. During the same period patient was treated with GEMCITABINE (2000mg Weekly Iv Drip) (View Gemcitabine Review and Gemcitabine Label ). Patient was hospitalized.

6466604-X | Cardiac Disorder, Fall
on Nov 13, 2009 Male patient from UNITED STATES , 75 years of age, weighting 211.9 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). Patient had the following side effects: cardiac disorder, fall (What is fall?). Erlotinib dosage: (150 Mg), Local Infiltration. During the same period patient was treated with BEVACIZUMAB (INJECTION FOR INFUSION) ((15 Mg/kg, Q3w, Intravenous) (View Bevacizumab (injection For Infusion) Review and Bevacizumab (injection For Infusion) Label ), TAXOL (View Taxol Review and Taxol Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ).

6454248-5 |
on Nov 19, 2009 Male patient from UNITED STATES , weighting 212.0 lb, was diagnosed with non-small cell lung cancer, hypertension, prophylaxis, arrhythmia (What is arrhythmia?) and was treated with Erlotinib (View Usage). . Erlotinib dosage: 150 Mg, Unk. During the same period patient was treated with AVASTIN (15 Mg/kg, Q3w) (View Avastin Review and Avastin Label ), TAXOL (200 Mg/m2, Q3w) (View Taxol Review and Taxol Label ), CARBOPLATIN (6 Auc, Q3w) (View Carboplatin Review and Carboplatin Label ), CLONIDINE (2 Mg, 1/week) (View Clonidine Review and Clonidine Label ), ASPIRIN (81 Mg, Qd) (View Aspirin Review and Aspirin Label ), LASIX (50 Mg, Qd) (View Lasix Review and Lasix Label ), LOSARTAN POTASSIUM (100 Mg, Qd) (View Losartan Potassium Review and Losartan Potassium Label ), SOTALOL HCL (60 Mg, Bid) (View Sotalol Hcl Review and Sotalol Hcl Label ).

6440510-9 |
Patient was taking Erlotinib (View Usage). on Nov 11, 2009 from UNITED STATES Additional patient health information: Male patient , weighting 212.0 lb, was diagnosed with non-small cell lung cancer and. Erlotinib dosage: 150 Mg, Unk. During the same period patient was treated with AVASTIN (15 Mg/kg, Q3w) (View Avastin Review and Avastin Label ), TAXOL (200 Mg/m2, Q3w) (View Taxol Review and Taxol Label ), CARBOPLATIN (6 Auc, Q3w) (View Carboplatin Review and Carboplatin Label ).

6428787-7 | Hyperbilirubinaemia
Adverse event was reported on Nov 04, 2009 by a Male patient taking Erlotinib (View Usage) (Dosage: 150 Mg Every Day Po) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , 83 years of age, Patient had the following side effects: hyperbilirubinaemia.

6428504-0 | Hepatic Enzyme Increased, Hyperbilirubinaemia
on Nov 04, 2009 Male patient from UNITED STATES , 74 years of age, was diagnosed with bladder cancer (What is bladder cancer?) and was treated with Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: hepatic enzyme increased, hyperbilirubinaemia. Erlotinib dosage: 150 Mg Everyday Po.

6427579-2 | Headache, Visual Impairment
on Oct 22, 2009 Female patient from UNITED KINGDOM , 49 years of age, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: headache (What is headache?), visual impairment. Erlotinib dosage: 150 Mg, Unk. During the same period patient was treated with BEVACIZUMAB (15 Mg/kg, Unk) (View Bevacizumab Review and Bevacizumab Label ), ZESTRIL (Unk) (View Zestril Review and Zestril Label ).

6417777-6 | Dyspnoea Exertional, Haemoglobin Decreased, Pulmonary Toxicity, Rectal Haemorrhage
Patient was taking Erlotinib (View Usage). Patient had the following side effects: dyspnoea exertional, haemoglobin decreased, pulmonary toxicity, rectal haemorrhage on Oct 27, 2009 from UNITED STATES Additional patient health information: Male patient , 60 years of age, weighting 222.7 lb, was diagnosed with pancreatic carcinoma and. Erlotinib dosage: 150mg Po Daily. During the same period patient was treated with ZOLPITEM (View Zolpitem Review and Zolpitem Label ), MEGESTROL ACETATE (View Megestrol Acetate Review and Megestrol Acetate Label ), OXYCODONE (View Oxycodone Review and Oxycodone Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), OXYCODONE HCL EXTENDED RELEASE (View Oxycodone Hcl Extended-release Review and Oxycodone Hcl Extended-release Label ), CALCIUM + VD (View Calcium + Vd Review and Calcium + Vd Label ), ASCORBIC ACID (View Ascorbic Acid Review and Ascorbic Acid Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ). Patient was hospitalized.

6407498-8 | Cough, Dyspnoea, Haemoptysis, Leukopenia, Lung Infection
Adverse event was reported on Sep 30, 2009 by a Male patient taking Erlotinib (View Usage) (Dosage: (150 Mg, Q21), Oral) was diagnosed with lung neoplasm malignant and. Location: GREECE , 71 years of age, After Erlotinib was administered, patient had the following side effects: cough, dyspnoea, haemoptysis, leukopenia, lung infection. During the same period patient was treated with DOCETAXEL (Intravenous) (View Docetaxel Review and Docetaxel Label ), LONALGAL (View Lonalgal Review and Lonalgal Label ), ZURCAZOL (View Zurcazol Review and Zurcazol Label ), REMERON (View Remeron Review and Remeron Label ), TILDIEM (DILTIAZEM) (View Tildiem (diltiazem) Review and Tildiem (diltiazem) Label ), DIOVAN HCT (View Diovan Hct Review and Diovan Hct Label ), SALOSPIR (ACETYLSALICYLIC ACID) (View Salospir (acetylsalicylic Acid) Review and Salospir (acetylsalicylic Acid) Label ), SPIRIVA (View Spiriva Review and Spiriva Label ). Patient was hospitalized.

6374419-6 | Gastric Haemorrhage
on Sep 15, 2009 Male patient from UNITED STATES , 56 years of age, weighting 204.8 lb, was treated with Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: gastric haemorrhage. Erlotinib dosage: 150 Mg Every Day Po. During the same period patient was treated with DICLOFENAC SODIUM (50 Mg Bid Po) (View Diclofenac Sodium Review and Diclofenac Sodium Label ). Patient was hospitalized.

6344651-6 | Disease Progression, Metastases To Meninges
on Aug 24, 2009 Female patient from UNITED KINGDOM , 56 years of age, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). Patient had the following side effects: disease progression, metastases to meninges. Erlotinib dosage: 150 Mg, Unk. During the same period patient was treated with BEVACIZUMAB (View Bevacizumab Review and Bevacizumab Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), PACLITAXEL (View Paclitaxel Review and Paclitaxel Label ).

6336647-5 | Haematemesis, Haematochezia, International Normalised Ratio Abnormal, Melaena, Somnolence, Vomiting
Patient was taking Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: haematemesis, haematochezia, international normalised ratio abnormal, melaena, somnolence, vomiting on Aug 31, 2009 from UNITED STATES Additional patient health information: Female patient , weighting 143.0 lb, was diagnosed with non-small cell lung cancer and. Erlotinib dosage: 100 Mg Qd Po. During the same period patient was treated with GEMCITABINE (Every Week Iv Drip) (View Gemcitabine Review and Gemcitabine Label ).

6336072-7 | Asthenia, Delirium, Fatigue
Adverse event was reported on Aug 31, 2009 by a Female patient taking Erlotinib (View Usage) (Dosage: 150mg Qd Po) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , 80 years of age, weighting 153.0 lb, Patient experienced the following unwanted or unexpected effects: asthenia, delirium, fatigue.

6336070-3 | Dizziness, Fall, Renal Failure Acute
on Aug 31, 2009 Female patient from UNITED STATES , 82 years of age, weighting 191.0 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). Patient had the following side effects: dizziness (What is dizziness?), fall (What is fall?), renal failure acute. Erlotinib dosage: 100 Mg Qd Po. Patient was hospitalized.

6306657-2 | Deep Vein Thrombosis, Electromechanical Dissociation, Implant Site Effusion, Muscle Spasms, No Therapeutic Response, Peritonitis, Pulmonary Embolism, Unresponsive To Stimuli
on Aug 11, 2009 Male patient from UNITED STATES , 71 years of age, weighting 111.0 lb, was diagnosed with squamous cell carcinoma and was treated with Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: deep vein thrombosis (What is deep vein thrombosis?), electromechanical dissociation, implant site effusion, muscle spasms, no therapeutic response, peritonitis, pulmonary embolism (What is pulmonary embolism?), unresponsive to stimuli. Erlotinib dosage: 150 Mg/qd. During the same period patient was treated with SULINDAC (150 Mg/qd) (View Sulindac Review and Sulindac Label ). Patient was hospitalized.

6302133-1 | Confusional State, Fatigue, Gastric Haemorrhage, Neuropathy Peripheral, Pneumonia, Syncope
Patient was taking Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: confusional state, fatigue, gastric haemorrhage, neuropathy peripheral, pneumonia (What is pneumonia?), syncope on Aug 04, 2009 from UNITED STATES Additional patient health information: Male patient , 73 years of age, weighting 158.7 lb, was diagnosed with lung adenocarcinoma, pain (What is pain?) and. Erlotinib dosage: 150 Mg, Qd. During the same period patient was treated with BEVACIZUMAB (15 Mg/kg, Q21d) (View Bevacizumab Review and Bevacizumab Label ), AVELOX (400 Mg, Qd) (View Avelox Review and Avelox Label ), ASPIRIN (81 Mg, Qd) (View Aspirin Review and Aspirin Label ), FLONASE (2 Puff, Unk) (View Flonase Review and Flonase Label ), ULTRAM (50 Mg, Prn) (View Ultram Review and Ultram Label ). Patient was hospitalized.

6299760-7 | Confusional State, Fatigue, Gastric Haemorrhage, Neuropathy Peripheral, Pneumonitis, Syncope
Adverse event was reported on Aug 01, 2009 by a Male patient taking Erlotinib (View Usage) (Dosage: 150 Mg, Qd) was diagnosed with lung adenocarcinoma, pain (What is pain?) and. Location: UNITED STATES , 73 years of age, weighting 158.7 lb, Patient had the following side effects: confusional state, fatigue, gastric haemorrhage, neuropathy peripheral, pneumonitis, syncope. During the same period patient was treated with BEVACIZUMAB (15 Mg/kg, Q21d) (View Bevacizumab Review and Bevacizumab Label ), AVELOX (400 Mg, Qd) (View Avelox Review and Avelox Label ), ASPIRIN (81 Mg, Qd) (View Aspirin Review and Aspirin Label ), FLONASE (2 Puff, Unk) (View Flonase Review and Flonase Label ), ULTRAM (50 Mg, Prn) (View Ultram Review and Ultram Label ). Patient was hospitalized.

6299646-8 | Dehydration, Dysgraphia, Gait Disturbance, Muscular Weakness, Speech Disorder, Transient Ischaemic Attack
on Aug 05, 2009 Female patient from UNITED STATES , weighting 143.0 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: dehydration, dysgraphia, gait disturbance, muscular weakness, speech disorder, transient ischaemic attack. Erlotinib dosage: 100 Mg Qd Po. During the same period patient was treated with GEMCITABINE (1706 Mg Every Week Iv Drip) (View Gemcitabine Review and Gemcitabine Label ). Patient was hospitalized.

6283008-3 | Mobility Decreased, Pain
on Jul 22, 2009 Female patient from UNITED STATES , 76 years of age, weighting 138.9 lb, was diagnosed with lung neoplasm malignant and was treated with Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: mobility decreased, pain (What is pain?). Erlotinib dosage: Daily. During the same period patient was treated with BEVACIZUMAB (Every 21 Days) (View Bevacizumab Review and Bevacizumab Label ). Patient was hospitalized.

6268162-1 | Renal Failure Acute
Patient was taking Erlotinib (View Usage). Patient had the following side effects: renal failure acute on Jul 13, 2009 from UNITED STATES Additional patient health information: Female patient , 69 years of age, weighting 81.00 lb, . Erlotinib dosage: 150 Mg Po Daily. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ). Patient was hospitalized.

6266936-4 | Convulsion, Disease Progression, Refusal Of Treatment By Patient
Adverse event was reported on Jul 10, 2009 by a Female patient taking Erlotinib (View Usage) (Dosage: 150 Mg, Po, Qday) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , weighting 152.3 lb, After Erlotinib was administered, patient had the following side effects: convulsion, disease progression, refusal of treatment by patient. During the same period patient was treated with LBH 589B (30 Mg, Po, #doses) (View Lbh 589b Review and Lbh 589b Label ), SENNA (View Senna Review and Senna Label ), MAGIC MOUTH WASH (View Magic Mouth Wash Review and Magic Mouth Wash Label ), MS CONTIN (View Ms Contin Review and Ms Contin Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), PROTONIX (View Protonix Review and Protonix Label ), ATIVAN (View Ativan Review and Ativan Label ).

6266762-6 | Disease Progression, Non-small Cell Lung Cancer, Pulmonary Embolism, Rectal Haemorrhage
on Jul 10, 2009 Male patient from UNITED STATES , weighting 157.0 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: disease progression, non-small cell lung cancer, pulmonary embolism (What is pulmonary embolism?), rectal haemorrhage. Erlotinib dosage: 100mg, Po, Qday. During the same period patient was treated with LBH 589B (30mg, Po, 4 Doses) (View Lbh 589b Review and Lbh 589b Label ), METHACIN (View Methacin Review and Methacin Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), OXYCODONE (View Oxycodone Review and Oxycodone Label ), PREVACID (View Prevacid Review and Prevacid Label ), CLINDAYCIN (View Clindaycin Review and Clindaycin Label ), FLUTICASONE (View Fluticasone Review and Fluticasone Label ), LACTULOSE (View Lactulose Review and Lactulose Label ). Patient was hospitalized.

6261572-8 | Abdominal Pain Upper, Diarrhoea, Nausea
on Jul 07, 2009 Male patient from UNITED STATES , 51 years of age, was diagnosed with lung neoplasm malignant and was treated with Erlotinib (View Usage). Patient had the following side effects: abdominal pain upper, diarrhoea, nausea (What is nausea?). Erlotinib dosage: 150 Mg Every Day Po. Patient was hospitalized.

6251199-6 | Haemoptysis
Patient was taking Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: haemoptysis on Jun 12, 2009 from UNITED KINGDOM Additional patient health information: Male patient , 63 years of age, weighting 149.5 lb, was diagnosed with non-small cell lung cancer and. Erlotinib dosage: (150 Mg,qd), Oral. During the same period patient was treated with CP 751, 871 (INJECTION FOR INFUSION) ((720 Mg), Intravenous) (View Cp-751, 871 (injection For Infusion) Review and Cp-751, 871 (injection For Infusion) Label ), SIMVASTATIN (SIMVASTATIN) (View Simvastatin (simvastatin) Review and Simvastatin (simvastatin) Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), CO CODAMOL (PANADEINE CO) (View Co-codamol (panadeine Co) Review and Co-codamol (panadeine Co) Label ), LOPERAMIDE (LOPERAMIDE) (View Loperamide (loperamide) Review and Loperamide (loperamide) Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ), AQUEOUS CREAM (AQUEOUS CREAM) (View Aqueous Cream (aqueous Cream) Review and Aqueous Cream (aqueous Cream) Label ). Patient was hospitalized.

6251189-3 | Haemoptysis, Musculoskeletal Pain
Adverse event was reported on Jun 12, 2009 by a Female patient taking Erlotinib (View Usage) (Dosage: (150 Mg, Qd), Oral) was diagnosed with non-small cell lung cancer and. Location: NETHERLANDS , 51 years of age, Patient experienced the following unwanted or unexpected effects: haemoptysis, musculoskeletal pain. During the same period patient was treated with BEVACIZUMAB (INJECTION FOR INFUSION) ((900 Mg,q3w), Intravenous) (View Bevacizumab (injection For Infusion) Review and Bevacizumab (injection For Infusion) Label ), PACLITAZEL (PACLITAXEL) (INJECTION FOR INFUSION) (Intravenous) (View Paclitazel (paclitaxel) (injection For Infusion) Review and Paclitazel (paclitaxel) (injection For Infusion) Label ), CARBOPLATIN (Intravenous) (View Carboplatin Review and Carboplatin Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), DIAZEPAM (View Diazepam Review and Diazepam Label ). Patient was hospitalized.

6242489-1 | Dyspnoea, Interstitial Lung Disease
on Jun 22, 2009 Male patient from UNITED STATES , weighting 135.0 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). Patient had the following side effects: dyspnoea, interstitial lung disease. Erlotinib dosage: 150 Mg Everyday Po.

6216750-0 | Chronic Obstructive Pulmonary Disease, Condition Aggravated, Pneumonia
on Jun 03, 2009 Female patient from UNITED STATES , weighting 123.7 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: chronic obstructive pulmonary disease, condition aggravated, pneumonia (What is pneumonia?). Erlotinib dosage: 1 150mg Po Every Day. During the same period patient was treated with DASATINIB (70mg Po Bid) (View Dasatinib Review and Dasatinib Label ), ALPRAXOLAM (View Alpraxolam Review and Alpraxolam Label ), ALBUTEROL PRN, PRETREATMENT (View Albuterol Prn, Pretreatment Review and Albuterol Prn, Pretreatment Label ), FOSAMAX, PRETREATMENT (View Fosamax, Pretreatment Review and Fosamax, Pretreatment Label ), ADVAIR, PRETREATMENT (View Advair, Pretreatment Review and Advair, Pretreatment Label ), CARDIAZEM, PRETREATMENT (View Cardiazem, Pretreatment Review and Cardiazem, Pretreatment Label ). Patient was hospitalized.

6196431-2 | Blood Albumin Decreased, Decreased Appetite, Diarrhoea, Dyspnoea, International Normalised Ratio Increased, Jaundice Cholestatic
Patient was taking Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: blood albumin decreased, decreased appetite, diarrhoea, dyspnoea, international normalised ratio increased, jaundice cholestatic on May 18, 2009 from UNITED STATES Additional patient health information: Male patient , 72 years of age, weighting 282.2 lb, . Erlotinib dosage: . During the same period patient was treated with VIT B12 (View Vit B12 Review and Vit B12 Label ), COMPAZINE (View Compazine Review and Compazine Label ), ATIVAN (View Ativan Review and Ativan Label ), COUMADIN (View Coumadin Review and Coumadin Label ), CEFUROXIME (View Cefuroxime Review and Cefuroxime Label ), DOXYCYCLINE (View Doxycycline Review and Doxycycline Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), PREVACID (View Prevacid Review and Prevacid Label ). Patient was hospitalized.

6190118-8 | Bronchitis, Pneumonia
Adverse event was reported on May 13, 2009 by a Female patient taking Erlotinib (View Usage) (Dosage: 150mg Po Every Day) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , weighting 145.7 lb, Patient had the following side effects: bronchitis (What is bronchitis?), pneumonia (What is pneumonia?). During the same period patient was treated with DASATINIB (70mg Po Bid) (View Dasatinib Review and Dasatinib Label ), COMBIVENT (View Combivent Review and Combivent Label ), ATIVAN (View Ativan Review and Ativan Label ), CARDIAZEM (View Cardiazem Review and Cardiazem Label ), LASIX (View Lasix Review and Lasix Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ), SINGULAIR (View Singulair Review and Singulair Label ), METHIMAZOLE (View Methimazole Review and Methimazole Label ). Patient was hospitalized.

6163801-8 | Rash, Skin Disorder
on Apr 07, 2009 Female patient from UNITED KINGDOM , 54 years of age, was diagnosed with lung adenocarcinoma and was treated with Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: rash (What is rash?), skin disorder. Erlotinib dosage: 150 Mg, Qd. During the same period patient was treated with AVASTIN (Unk) (View Avastin Review and Avastin Label ).

6143863-4 | Dehydration, Nausea, Pyrexia
on Mar 30, 2009 Male patient from UNITED STATES , weighting 127.5 lb, was diagnosed with nasopharyngeal cancer and was treated with Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: dehydration, nausea (What is nausea?), pyrexia. Erlotinib dosage: 100 Mg, Qd. During the same period patient was treated with BEVACIZUMAB (10 Mg/kg, Unk) (View Bevacizumab Review and Bevacizumab Label ), CISPLATIN (50 Mg, Unk) (View Cisplatin Review and Cisplatin Label ), ONDANSETRON (15 Mg, Unk) (View Ondansetron Review and Ondansetron Label ), ACETAMINOFEN (650 Mg, Unk) (View Acetaminofen Review and Acetaminofen Label ), DEXAMETHASONE (20 Mg, Unk) (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6142730-X | Convulsion, Lung Neoplasm, Malignant Neoplasm Progression, Metastases To Central Nervous System, Pulmonary Mass, Unresponsive To Stimuli, Vasogenic Cerebral Oedema
Patient was taking Erlotinib (View Usage). Patient had the following side effects: convulsion, lung neoplasm, malignant neoplasm progression, metastases to central nervous system, pulmonary mass, unresponsive to stimuli, vasogenic cerebral oedema on Apr 02, 2009 from UNITED STATES Additional patient health information: Female patient , weighting 130.3 lb, was diagnosed with non-small cell lung cancer and. Erlotinib dosage: 150 Mg Qd Po. Patient was hospitalized.

6142688-3 | Disease Progression
Adverse event was reported on Apr 02, 2009 by a Female patient taking Erlotinib (View Usage) (Dosage: 150 Mg Qd Po) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , weighting 130.3 lb, After Erlotinib was administered, patient had the following side effects: disease progression.

6124013-7 | Disease Progression
on Mar 18, 2009 Female patient from UNITED STATES , weighting 108.5 lb, was diagnosed with lung neoplasm malignant and was treated with Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: disease progression. Erlotinib dosage: 150 Mg Daily Po. During the same period patient was treated with SUNITINIB (37.5 Mg Daily Po) (View Sunitinib Review and Sunitinib Label ).

6092896-5 | Constipation, Dehydration, Nausea, Pyrexia
on Feb 20, 2009 Male patient from UNITED STATES , weighting 127.5 lb, was diagnosed with nasopharyngeal cancer and was treated with Erlotinib (View Usage). Patient had the following side effects: constipation (What is constipation?), dehydration, nausea (What is nausea?), pyrexia. Erlotinib dosage: 100 Mg, Qd. During the same period patient was treated with BEVACIZUMAB (10 Mg/kg, Unk) (View Bevacizumab Review and Bevacizumab Label ), CISPLATIN (50 Mg, Unk) (View Cisplatin Review and Cisplatin Label ), ONDANSETRON (15 Mg, Unk) (View Ondansetron Review and Ondansetron Label ), ACETAMINOFEN (650 Mg, Unk) (View Acetaminofen Review and Acetaminofen Label ), DEXAMETHASONE (20 Mg, Unk) (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6087966-1 | Dehydration, Hypophagia, Lymphopenia, Pyrexia, White Blood Cell Count Decreased
Patient was taking Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: dehydration, hypophagia, lymphopenia, pyrexia, white blood cell count decreased on Feb 19, 2009 from UNITED STATES Additional patient health information: Male patient , weighting 127.5 lb, was diagnosed with nasopharyngeal cancer and. Erlotinib dosage: 100 Mg, Qd. During the same period patient was treated with BEVACIZUMAB (10 Mg/kg, Unk) (View Bevacizumab Review and Bevacizumab Label ), CISPLATIN (50 Mg, Unk) (View Cisplatin Review and Cisplatin Label ), ONDANSETRON (15 Mg, Unk) (View Ondansetron Review and Ondansetron Label ), ACETAMINOFEN (650 Mg, Unk) (View Acetaminofen Review and Acetaminofen Label ), DEXAMETHASONE TAB (20 Mg, Unk) (View Dexamethasone Tab Review and Dexamethasone Tab Label ). Patient was hospitalized.

6084308-2 | Abdominal Pain, Abdominal Wall Mass
Adverse event was reported on Feb 17, 2009 by a Female patient taking Erlotinib (View Usage) (Dosage: 150mg, Po Daily) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , weighting 150.4 lb, Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), abdominal wall mass. During the same period patient was treated with DASATINIB (140mg , Po Daily) (View Dasatinib Review and Dasatinib Label ). Patient was hospitalized.

6083054-9 | Dehydration, Hypophagia, Lymphopenia, Pyrexia, White Blood Cell Count Decreased
on Feb 13, 2009 Male patient from UNITED STATES , weighting 127.5 lb, was diagnosed with nasopharyngeal cancer and was treated with Erlotinib (View Usage). Patient had the following side effects: dehydration, hypophagia, lymphopenia, pyrexia, white blood cell count decreased. Erlotinib dosage: 100 Mg, Qd. During the same period patient was treated with BEVACIZUMAB (10 Mg/kg, Unk) (View Bevacizumab Review and Bevacizumab Label ), CISPLATIN (50 Mg, Unk) (View Cisplatin Review and Cisplatin Label ), ONDANSETRON (15 Mg, Unk) (View Ondansetron Review and Ondansetron Label ), ACETAMINOFEN (650 Mg, Unk) (View Acetaminofen Review and Acetaminofen Label ), DEXAMETHASONE TAB (20 Mg, Unk) (View Dexamethasone Tab Review and Dexamethasone Tab Label ). Patient was hospitalized.

6074701-6 | Deep Vein Thrombosis, Disease Recurrence, Lung Adenocarcinoma Metastatic, Malignant Pleural Effusion
on Feb 10, 2009 Male patient from UNITED STATES , weighting 211.6 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: deep vein thrombosis (What is deep vein thrombosis?), disease recurrence, lung adenocarcinoma metastatic, malignant pleural effusion. Erlotinib dosage: 150mg, Po Daily. During the same period patient was treated with DASATINIB (140mg Po Daily) (View Dasatinib Review and Dasatinib Label ). Patient was hospitalized.

6069476-0 | Pneumomediastinum
Patient was taking Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: pneumomediastinum on Feb 03, 2009 from UNITED STATES Additional patient health information: Male patient , 32 years of age, weighting 135.6 lb, was diagnosed with bile duct cancer and. Erlotinib dosage: 150 Mg, Qd. During the same period patient was treated with BEVACIZUMAB (5 Mg/kg, Days 1+15) (View Bevacizumab Review and Bevacizumab Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), AMBIEN (View Ambien Review and Ambien Label ), ACTIQ (View Actiq Review and Actiq Label ), METHADONE HCL (View Methadone Hcl Review and Methadone Hcl Label ). Patient was hospitalized.

6024147-1 | Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Lactate Dehydrogenase Increased, Diarrhoea, Erythema, Gamma-glutamyltransferase Increased, Hepatotoxicity, Malignant Neoplasm Progression, Non-small Cell Lung Cancer
Adverse event was reported on Dec 17, 2008 by a Female patient taking Erlotinib (View Usage) (Dosage: (150 Mg,qd), Oral) was diagnosed with non-small cell lung cancer and. Location: GERMANY , 68 years of age, Patient had the following side effects: aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, diarrhoea, erythema, gamma-glutamyltransferase increased, hepatotoxicity, malignant neoplasm progression, non-small cell lung cancer. During the same period patient was treated with TRAMADOL HYDROHLORIDE (View Tramadol Hydrohloride Review and Tramadol Hydrohloride Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), NOVALGIN (METAMIZOLE SODIUM) (View Novalgin (metamizole Sodium) Review and Novalgin (metamizole Sodium) Label ), VOLTAREN (View Voltaren Review and Voltaren Label ), ECURAL (MOMETASONE FUROATE) (View Ecural (mometasone Furoate) Review and Ecural (mometasone Furoate) Label ). Patient was hospitalized.

6015224-X | Cerebral Haemorrhage, Hypertension
on Dec 19, 2008 Male patient from UNITED STATES , 81 years of age, weighting 179.0 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotinib (View Usage). After Erlotinib was administered, patient had the following side effects: cerebral haemorrhage, hypertension. Erlotinib dosage: 50 Mg Daily X 96 Days. During the same period patient was treated with SORAFENIB (200 Mg Bid X 70 Days) (View Sorafenib Review and Sorafenib Label ). Patient was hospitalized.

6000656-6 | Cytogenetic Abnormality, Pulmonary Embolism
on Nov 25, 2008 Male patient from GERMANY , 66 years of age, was diagnosed with pancreatic carcinoma metastatic and was treated with Erlotinib (View Usage). Patient experienced the following unwanted or unexpected effects: cytogenetic abnormality, pulmonary embolism (What is pulmonary embolism?). Erlotinib dosage: 100 Mg, Oral. During the same period patient was treated with GEMCITABINE (2100 Mg, Qw, Intaveneous) (View Gemcitabine Review and Gemcitabine Label ), ESOMEPRAZOLE MAGNESIUM (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), NOVALGIN (METAMIZOLE SODIUM) (View Novalgin (metamizole Sodium) Review and Novalgin (metamizole Sodium) Label ), IBUPROFEN TABLETS (View Ibuprofen Tablets Review and Ibuprofen Tablets Label ), FRAXIPARIN (HEPARIN FRACTION, CALCIUM SALT) (View Fraxiparin (heparin-fraction, Calcium Salt) Review and Fraxiparin (heparin-fraction, Calcium Salt) Label ), ZOFRAN (View Zofran Review and Zofran Label ), TRAIMTEREN COMP (View Traimteren Comp Review and Traimteren Comp Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ). Patient was hospitalized.

5999688-3 | Hypotension, Renal Failure Acute, Rhabdomyolysis, Shock
Patient was taking Erlotinib (View Usage). Patient had the following side effects: hypotension, renal failure acute, rhabdomyolysis, shock on Dec 11, 2008 from UNITED STATES Additional patient health information: Male patient , 64 years of age, was diagnosed with bile duct cancer, pancreatic carcinoma and. Erlotinib dosage: 150 Mg Po Daily. During the same period patient was treated with GEMCITABINE HCL (View Gemcitabine Hcl Review and Gemcitabine Hcl Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), SENOKOT (View Senokot Review and Senokot Label ), KLONOPIN (View Klonopin Review and Klonopin Label ), MS CONTIN (View Ms Contin Review and Ms Contin Label ). Patient was hospitalized.